Physician profile
David Collins
NPI 1588195648
$1,701.20
in general payments reported to CMS, 2019-2025
25 companies · $579 in 2025
The $579 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $20.36 · 2022: $398 · 2023: $252 · 2024: $339 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $273.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $262.86 | 2023-2025 | |
| Amgen INC. | $206.68 | 2022-2025 | Uplizna, Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $153.80 | 2023-2025 | Lifevest |
| Pfizer INC. | $130.00 | 2019-2024 | |
| Impulse Dynamics (USA) INC. | $124.59 | 2021-2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $67.74 | 2023-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $53.06 | 2024 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $49.60 | 2025 | |
| Novo Nordisk INC | $49.21 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $49.16 | 2023-2025 | Farxiga, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $37.56 | 2025 | |
| Scpharmaceuticals INC. | $27.30 | 2025 | |
| Irhythm Technologies, INC. | $26.90 | 2024 | Zio Monitor, Zio Xt Patch |
| Heartflow, INC. | $22.74 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20.52 | 2024 | Watchman Flx |
| Cvrx, INC. | $19.57 | 2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.96 | 2024 | Jardiance |
| Ionis Pharmaceuticals, INC. | $18.52 | 2025 | Tryngolza |
| Watermark Medical, INC. | $18.09 | 2025 | |
| Medicomp INC | $15.24 | 2025 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals, Ltd. | $14.77 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $14.73 | 2023 | Verquvo |
| Terumo Medical Corporation | $13.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.76 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.